Improvement of affinity and potency of a monoclonal antibody against Shigella flexneri 3a O-antigen via phage display and whole-cell in-solution panning
Nicholas L. XerriiD, Sophia PulidoiD, Mateusz KędzioriD, Paul SavarinoiD, Torrey Williams, Robert M. GallantiD, Robert W. KaminskiiD, Devin SokiD, Hayden R. SchmidtiD
Abstract
As rates of antimicrobial resistance (AMR) among bacterial pathogens continue to rise, the discovery and development of novel classes of therapeutics that can serve as alternatives or adjuncts to traditional small-molecule antibiotics, such as monoclonal antibodies (mAbs), is a public health priority. Some of the most promising antigen targets for antibacterial mAbs are surface polysaccharides such as O-antigen (O-Ag), a component of the lipopolysaccharide found on the outer membrane of gram-negative bacteria. However, developing mAbs against bacterial surface polysaccharides with sufficient breadth and potency to be clinically viable is difficult in part because antibodies against polysaccharides are generally low affinity, and the challenging biochemistry of polysaccharides often precludes further affinity maturation of mAbs against these targets in vitro. Here, we use a phage display library and a whole-cell in-solution panning strategy to successfully improve the affinity of a mAb against Shigella flexneri 3a O-Ag in vitro without requiring the purification of the target antigen. We demonstrate that a single mutation can improve apparent affinity approximately 10-fold without detectably increasing polyreactivity, and increased affinity correlates with enhanced potency in antibacterial effector function and anti-virulence assays. In addition, the most potent variants also gained increased breadth, successfully coordinating complement deposition and complement-independent opsonophagocytosis against S. flexneri 3b, a serotype weakly recognized by the parent mAb. Altogether, this work represents an important first step towards expanding the antibody engineering toolkit for bacterial surface polysaccharides, which will aid the development of novel mAb therapeutics against AMR bacterial pathogens.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 1
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Protective and pathogenic antibody responses from a primate Shigella outbreak inform vaccine design
Robert M. Gallant, Paul Savarino, … Hayden R. Schmidt·bioRxiv·Dec 19, 2025
- A novel therapeutic antibody screening method using bacterial high-content imaging reveals functional antibody binding phenotypes of Escherichia coli ST131
M. Maes, Z. A. Dyson, … J. Bartholdson Scott·bioRxiv·May 22, 2020
- The increased hinge flexibility of an IgG1-IgG3 hybrid monoclonal enhances Fc-mediated protection against group A streptococci
A. Izadi, Y. Karami, … P. Nordenfelt·bioRxiv·Oct 14, 2023
- Promoting Fc-Fc interactions between anti-capsular antibodies provides strong complement-dependent immune protection against Streptococcus pneumoniae
L. Aguinagalde, M. A. den Boer, … S. Rooijakkers·bioRxiv·Jan 21, 2022
- Platform for Identifying Human Glycan-Specific Antibodies Against Bacterial Pathogens using Synthetic Glycan Fragments
A. Robin Temming, Mathieu A. F. Claireaux, … Nina M. van Sorge·bioRxiv·Aug 19, 2025
- Outer membrane vesicles derived from Salmonella Typhimurium can deliver Shigella flexneri 2a O-polysaccharide antigen to prevent lethal pulmonary infection in mice